Stock comparison
Genmab A/S
Galapagos N.V. Sponsored ADR
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
LKFT
Galapagos N.V. Sponsored ADR
Market cap
$1.81B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | LKFT | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 46D | GMAB |
| Benjamin Graham | 64C | 45D | GMAB |
| Philip Fisher | 48D | 53C | LKFT |
| Peter Lynch | 25F | 60C | LKFT |
| Joel Greenblatt | 76B | 42D | GMAB |
| Charlie Munger | 68C | 46D | GMAB |
| Terry Smith | 71C | 46D | GMAB |
Side-by-side metrics
| Metric | GMAB | LKFT |
|---|---|---|
| Market cap | $16.5B | $1.81B |
| P/E (TTM) | 6.2x | 3.1x |
| EV/EBIT | 12.0x | 2.9x |
| ROIC (TTM) | 43.78% | 18.22% |
| Gross margin | 93.88% | 98.01% |
| Net margin | 18.23% | 46.83% |
| Revenue CAGR 5y | -18.45% | - |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $1.81B+89%
- ROIC (TTM)43.78%vs 18.22%+58%
LKFT leads on
- Debt / Equity0.0xvs 0.1x+97%
- EV/EBIT2.9xvs 12.0x+75%
- Net margin46.83%vs 18.23%+61%
- P/E (TTM)3.1xvs 6.2x+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.